Ashley Gallagher, MA

Clinicians separate idiopathic hypersomnia from depression-related sleepiness and interpret real-world and trial data for better outcomes.

Cleveland Clinic's Beth Faiman, PhD, MSN, says fast-moving myeloma care requires funded education and fewer barriers for advanced practitioner-led care.

UChicago Medicine’s Obada Shamaa, MD, PhD, discusses why bronchiectasis is underrecognized and how to personalize airway clearance and antibiotic plans.

Stanford's Richard Lafayette discusses 36-week povetacicept data in IgA nephropathy, including proteinuria, hematuria, and safety findings.

Seven oncology leaders at PCOC in Nashville share what patient-centered care means today and how they want it to change over the next 5 years.

Experts spot idiopathic hypersomnia when tests miss it, using symptom scales, targeted questions, wearables, and shared treatment choices.

Karolinska Institutet’s Antoine Créon, MD, explains how alert fatigue, workflow, and center-level variation may have limited a CKD alert trial.

OneOncology's Larry Bilbrey outlines network-level contracting, data security, physician review of AI output, and clear vendor lanes for AI.

UW Medicine’s Bessie A. Young, MD, MPH, explains how high-risk APOL1 variants, ancestry, and environmental factors shape kidney disease risk.

Providence’s Katherine R. Tuttle, MD, FASN, explains why semaglutide is preferred in T2D and CKD and how guidelines sequence added therapies.

Columbia’s Jai Radhakrishnan, MD, MS, explains how FSGS differs by phenotype and why new IgA nephropathy drugs reach so few patients.

Karolinska Institutet’s Antoine Créon, MD, discusses why CKD alerts did not improve screening, retesting, or diagnosis in Stockholm primary care.

Tennessee Oncology’s Johnetta Blakely, MD, MS, discusses how AI could ease workforce strain, support quality tracking, and the barriers to adopting it.

OneOncology's Edward "Ted" Arrowsmith, MD, MPH, explains how pathways keep pace with new approvals and why real-time data will shape their future.

Tennessee Oncology's Wade Iams, MD, MSCI, discusses staffing and tocilizumab access as barriers to expanding BiTE therapy and the costs of cell therapy.

Weill Cornell's Mateo Mejia Saldarriaga, MD, explains why IVIG, infection monitoring, and deeper bridging responses matter with myeloma immunotherapy.

Narcolepsy and idiopathic hypersomnia can go undiagnosed for years, and Epworth and RU-SATED screening help clinicians spot true sleepiness sooner.

OneOncology's Larry Bilbrey explains how to guide practices on AI without endorsing products and why technology gaps outweigh workflow problems.

COA's Nicolas Ferreyros discusses next steps for PBM reform, funding for supportive cancer services, and a hopeful outlook for community oncology.

Cleveland Clinic's Beth Faiman, PhD, MSN, discusses advanced practitioners' reimbursement and how outpatient trispecific antibodies could increase access.

Tennessee Oncology’s Johnetta Blakely, MD, MS, explains why physicians must review high-stakes AI-assisted orders and how patients view AI in oncology.

OneOncology's Edward "Ted" Arrowsmith, MD, MPH, explains why cost stays out of its pathway process and how point-of-care ordering puts pathways to work.

Tennessee Oncology's Wade Iams, MD, MSCI, discusses insured patients' out-of-pocket costs, platinum shortages, and access to CAR T and BiTE therapies.

Cathy Eng, MD, says flat funding for NCI-sponsored trials discourages site participation and slows data, despite their importance.

OneOncology's Larry Bilbrey discusses why unstructured data limits artificial intelligence and how practices can weigh AI purchases by their payoff.

Weill Cornell's Mateo Mejia Saldarriaga, MD, discusses patient preference for on-body isatuximab and how to sequence CAR T and bispecifics in myeloma.

COA's Nicolas Ferreyros discusses real-world survival data for community oncology, health system consolidation, and barriers to CAR T-cell access.

Washington, DC, clinicians shared how order sets, pharmacist-led dosing, and better handoffs can close iron deficiency gaps in heart failure care.

Cathy Eng, MD, discusses a BREAKWATER post hoc analysis showing poorer survival in early-onset BRAF V600E colorectal cancer.

Cleveland Clinic's Beth Faiman, PhD, MSN, discusses AP-led clinics, managing talquetamab taste changes, and infection prophylaxis with bispecifics.